GARFIELD-AF Risk Score
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years
حداقل ۳۰ — حداکثر ۳۰۰ • واحد: kg
حداقل ۳۰ — حداکثر ۲۵۰ • واحد: bpm
حداقل ۴۰ — حداکثر ۱۵۰ • واحد: mmHg
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–2
- Moderate Risk2–5
- High Risk5–100
The GARFIELD-AF Risk Score calculates predicting 1- and 2-year risks of mortality, ischemic stroke/systemic embolism, and major bleeding in patients with atrial fibrillation. Key inputs include age. Scores guide initiating guideline-directed medical therapy, antithrombotic or anticoagulant regimens, or urgent coronary angiography. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
The GARFIELD-AF risk score simultaneously predicts 1- and 2-year risks of mortality, ischemic stroke/systemic embolism, and major bleeding in patients with atrial fibrillation. This contemporary risk stratification tool incorporates 16 clinical variables and has been validated across diverse international populations with both anticoagulated and non-anticoagulated patients.
Clinical Indication
The GARFIELD-AF Risk Score is indicated for bedside clinical practice to support The GARFIELD-AF risk score simultaneously predicts 1- and 2-year risks of mortality, ischemic stroke/systemic embolism, and major bleeding in patients with atrial fibrillation. This contemporary risk stratification tool incorporates 16 clinical variables and has been validated across diverse international populations with both anticoagulated and non-anticoagulated patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.
Limitations & Contraindications
In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.
Clinical Pearls & Action Plan
Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines. Guideline pearl: Regular re-evaluation is recommended as clinical status changes may affect risk predictions.
Complex regression model with 16 variables predicting simultaneous risks of mortality, ischemic stroke/systemic embolism, and major bleeding at 1 and 2 years using validated coefficients from GARFIELD-AF registry
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Patient's age in years(years) |
| weight | float | Yes | Patient's body weight(kg) |
| race | string | Yes | Patient's race/ethnicity |
| sex | string | Yes | Patient's biological sex |
| pulse | integer | Yes | Heart rate in beats per minute(bpm) |
| diastolic_bp | integer | Yes | Diastolic blood pressure(mmHg) |
| history_of_bleeding | string | Yes | History of major bleeding episodes |
| heart_failure | string | Yes | History of heart failure or reduced ejection fraction |
| history_of_stroke | string | Yes | History of stroke or transient ischemic attack |
| chronic_kidney_disease | string | Yes | Chronic kidney disease or renal impairment |
| vascular_disease | string | Yes | Vascular disease (coronary artery disease, peripheral arterial disease, or aortic plaque) |
| diabetes_mellitus | string | Yes | Diabetes mellitus requiring medication |
| current_smoking | string | Yes | Current tobacco smoking status |
| dementia | string | Yes | History of dementia or cognitive impairment |
| antiplatelet_use | string | Yes | Current use of antiplatelet medications (aspirin, clopidogrel, etc.) |
| carotid_disease | string | Yes | Carotid artery disease or stenosis |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–2 | Low Risk | Low risk across all outcomes |
| 2–5 | Moderate Risk | Moderate risk requiring careful monitoring |
| 5–100 | High Risk | High risk requiring intensive management |
Evidence-Based References (EBM)
- Fox KAA, Lucas JE, Pieper KS, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017;7(12):e017157. doi: 10.1136/bmjopen-2017-017157.DOI: 10.1136/bmjopen-2017-017157
- Apenteng PN, Murray ET, Holder R, et al. An international longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13-19.e1. doi: 10.1016/j.ahj.2011.09.011.DOI: 10.1016/j.ahj.2011.09.011
- Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307-314. doi: 10.1136/heartjnl-2016-309832.DOI: 10.1136/heartjnl-2016-309832